[Inflammation, atherosclerosis, classic cardiovascular risk factors, biostatistics, clinical significance. Where are we?].
García-Moll
Xavier
X
D054058:Acute Coronary Syndrome / Q000097:blood*; D050197:Atherosclerosis / Q000209:etiology*; D001699:Biometry; D050171:Dyslipidemias / Q000188:drug therapy*; D005464:Fluorobenzenes / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006973:Hypertension / Q000188:drug therapy*; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007249:Inflammation / Q000188:drug therapy; D008687:Metformin / Q000627:therapeutic use; D018384:Oxidative Stress / Q000187:drug effects; D011743:Pyrimidines / Q000627:therapeutic use; D012307:Risk Factors; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000097:blood*
D005464:Fluorobenzenes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007004:Hypoglycemic Agents; D011743:Pyrimidines; D013449:Sulfonamides; D014409:Tumor Necrosis Factor-alpha; D000068718:Rosuvastatin Calcium; D008687:Metformin